GlassScriptPhysician profile
Brandee Marksberry
NPI 1578942348
$2,818.75
in general payments reported to CMS, 2019-2025
20 companies · $766 in 2025
The $766 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $624 · 2022: $462 · 2023: $408 · 2024: $558 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $670.87 | 2021-2025 | Caplyta |
| Abbvie INC. | $431.50 | 2021-2025 | |
| Axsome Therapeutics, INC. | $347.13 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $287.46 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $155.02 | 2021-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $126.23 | 2021-2024 | |
| Lundbeck LLC | $115.43 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $108.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.17 | 2024 | Cobenfy |
| Alkermes, INC. | $90.72 | 2022 | |
| Corium, LLC | $77.36 | 2022-2024 | Azstarys |
| Tris Pharma INC | $73.85 | 2022-2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $67.56 | 2024-2025 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $50.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $33.47 | 2023-2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $22.43 | 2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $19.92 | 2024 | Fanapt |
| Janssen Pharmaceuticals, INC | $17.84 | 2023 | Spravato |
| Supernus Pharmaceuticals, INC. | $13.60 | 2022 | |
| Bausch Health US, LLC | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandee Marksberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.